Novartis Net Working Capital from 2010 to 2024

NVS Stock  USD 92.57  0.51  0.55%   
Novartis Net Working Capital yearly trend continues to be comparatively stable with very little volatility. Net Working Capital is likely to outpace its year average in 2024. From the period from 2010 to 2024, Novartis Net Working Capital quarterly data regression had mean square error of 15727077.9 T and mean deviation of  2,030,408,889. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
4.1 B
Current Value
5.7 B
Quarterly Volatility
3.9 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 B, Interest Expense of 550.6 M or Selling General Administrative of 15 B, as well as many exotic indicators such as Price To Sales Ratio of 3.66, Dividend Yield of 0.0254 or PTB Ratio of 3.07. Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.
  
This module can also supplement Novartis' financial leverage analysis and stock options assessment as well as various Novartis Technical models . Check out the analysis of Novartis Correlation against competitors.

Latest Novartis' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Novartis AG ADR over the last few years. It is Novartis' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novartis' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Pretty Stable
   Net Working Capital   
       Timeline  

Novartis Net Working Capital Regression Statistics

Arithmetic Mean5,055,733,333
Coefficient Of Variation76.25
Mean Deviation2,030,408,889
Median4,805,000,000
Standard Deviation3,854,898,525
Sample Variance14860242.6T
Range18.9B
R-Value0.13
Mean Square Error15727077.9T
R-Squared0.02
Significance0.64
Slope113,253,571
Total Sum of Squares208043396.9T

Novartis Net Working Capital History

20245.7 B
20234.1 B
20228.3 B
202115.5 B
2020-3.4 B
20191.2 B
2018B

About Novartis Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Novartis income statement, its balance sheet, and the statement of cash flows. Novartis investors use historical funamental indicators, such as Novartis's Net Working Capital, to determine how well the company is positioned to perform in the future. Although Novartis investors may use each financial statement separately, they are all related. The changes in Novartis's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novartis's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novartis Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novartis. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital4.1 B5.7 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:
Check out the analysis of Novartis Correlation against competitors.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
4.987
Dividend Share
3.919
Earnings Share
4.1
Revenue Per Share
22.467
Quarterly Revenue Growth
0.074
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.